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Abstract
Background: Renal cell carcinoma (RCC) are accompanied by inferior vena cava (IVC) thrombus in up to 10% of the
cases, with surgical resection remaining the only curative option. In case of IVC wall invasion, the operative
procedure is more challenging and may even require IVC resection. This study aims to determine the diagnostic
performance of contrast-enhanced magnetic resonance imaging (MRI) for the assessment of wall invasion by IVC
thrombus in patients with RCC, validated with intraoperative findings.
Methods: Data were collected on 81 patients with RCC and IVC thrombus, who received a radical nephrectomy and
vena cava thrombectomy between February 2008 and November 2017. Forty eight patients met the inclusion criteria.
Sensitivity and specificity as well as the positive and negative predictive values were calculated for preoperative MRI,
based on the assessments of the two readers for visual wall invasion. Furthermore, a logistic regression model was
used to determine if there was an association between intraoperative wall adherence and IVC diameter.
Results: Complete occlusion of the IVC lumen or vessel breach could reliably assess IVC wall invasion with a sensitivity of
92.3% (95%-CI: 0.75–0.99) and a specificity of 86.4% (95%-CI: 0.65–0.97) (Fisher-test: p-value< 0.001). The positive predictive
value (PPV) was 88.9% (95%-CI: 0.71–0.98) and the negative predictive value reached 90.5% (95%-CI: 0.70–0.99). There was
an excellent interobserver agreement for determining IVC wall invasion with a kappa coefficient of 0.90 (95%CI: 0.79–1.00).
Conclusions: The present study indicates that standard preoperative MR imaging can be used to reliably assess IVC wall
invasion, evaluating morphologic features such as the complete occlusion of the IVC lumen or vessel breach. Increases in
IVC diameter are associated with a higher probability of IVC wall invasion.
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Background
Renal cell carcinoma (RCC) represent approximately 2–
3% of all tumors and show a propensity for vascular
growth with up to 10% of patients developing an inferior
vena cava (IVC) thrombus [1, 2]. IVC wall invasion is a
negative prognostic factor [3], whereby positive renal or
caval vein margins are associated with worse survival out-
comes [4, 5]. To date, surgical resection remains the only
curative option, offering a 5-year-survival of up to 40–65%
for RCC with intravascular growth, which is reduced in
cases with IVC wall invasion [6–8].
In case of IVC wall invasion, surgery is more challenging,
because it may necessitate segmental resection or even
prosthetic replacement to prevent postoperative recurrence
or venous insufficiency [9, 10]. The need for segmental
resection or prosthetic replacement is typically determined
intraoperatively. Therefore, the ability to predict IVC inva-
sion preoperatively would be a clear advantage in terms of
preoperative planning and a priori patient information.
High quality diagnostic imaging is a cornerstone of
preoperative planning and management. With regard to
the presence and extent of IVC invasion, MR is a powerful
* Correspondence: Lisa.adams@charite.de
†Equal contributors
1Department of Radiology, Charité, Charitéplatz 1, 10117 Berlin, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Adams et al. Cancer Imaging  (2018) 18:17 
https://doi.org/10.1186/s40644-018-0150-z
and accurate tool and is suggested to be more reliable than
computed tomography (CT) [11]. However, data on the
prediction of venous wall invasion by preoperative imaging
are sparse. There have been only a limited number of stud-
ies - most of them with older generation MR scanners and
a small number of patients - investigating the ability of CT
or MRI to assess the extent of wall invasion and vena caval
tumor extension [7, 9, 12–14]. While breach of the vessel
wall with tumor signal on both sides of the vessel wall has
been demonstrated to be a reliable sign of IVC wall inva-
sion [9, 15], contact of the IVC thrombus with the vessel
wall could not be established as a reliable predictor so far.
Methods
In the present study, we aimed to evaluate the accuracy
of preoperative standard MRI for determining or ruling
out wall invasion of the IVC, based on morphologic fea-
tures such as vessel wall contact or vessel wall breach,
with imaging findings being validated with intraoperative
results. Furthermore, we sought to test for the potential
association between wall invasion and IVC diameter or
thrombus enhancement.
Study design and population
This retrospective study was approved by the Institu-
tional Review Board. Between February 2008 and No-
vember 2017, 81 patients with histologically proven RCC
and IVC thrombus received a radical nephrectomy and
vena cava thrombectomy with an intraoperative assess-
ment of IVC wall invasion. Of these patients, 48 patients
obtained a preoperative MRI examination with a clinical
routine protocol at a 1.5 T unit and could be included in
our analysis, aiming to validate in vivo findings of IVC
wall invasion with intraoperative findings.
The patient sample consisted of a total of 48 patients
(10 women and 38 men, aged 38–79, mean 64.9 ± 9.8).
The median time between the preoperative imaging and
the date of surgery was 16.1 (± 13.3) days. With regard
to the composition of the thrombus, there were 8 pa-
tients with bland thrombus (0 cases IVC wall invasion),
19 patients with tumor thrombus (16 cases with wall in-
vasion) and 21 patients with mixed content (10 cases
with wall invasion), whereby mixed content refers to a
coexistence of bland thrombus and tumor thrombus.
Circumferential cavectomy with prosthetic replacement
of the IVC was performed in only 3 of the 48 patients
(6.3%), whereas the other patients received a reconfigur-
ation with continuous suturing. In the 3 cases with cir-
cumferential cavectomy, IVC tumor invasion was
histologically confirmed. In 9 of the 48 patients (18.8%)
with level IV thrombi, a cardiopulmonary bypass had to
be used. During histological examination, 40 of the pa-
tients were revealed to have a clear cell RCC, seven pa-
tients showed papillary carcinomas and one patients had
an undifferentiated renal carcinoma, which could not be
clearly classified. An overview of the patients’ character-
istics is provided by Table 1.
Imaging protocol
The MRI examinations from our hospital were per-
formed on 1.5 T units (Aera/Avanto/Symphony/Sonata,
Siemens Medical Solutions, Erlangen, Germany) with
dedicated body-phased-array coils. All patients under-
went a clinical routine imaging of the kidneys at 1.5 T,
which included transverse, coronal and sagittal T2 half
Fourier single-shot turbo spin echo sequences (HASTE),
unenhanced axial 3D gradient echo pulse T1-weighted
(FLASH) images, a T1- FLASH angiography, obtained
prior to and after the intravenous administration of con-
trast agents, and a fat saturated volumetric interpolated
breath-hold examination (VIBE) T1 3D sequence (see
Table 2 for tabulated magnetic resonance imaging
parameters).
Level of IVC extent, tumor thrombus enhancement and
IVC diameter
Level of IVC extent was stratified following the classifi-
cation of tumor thrombus level according to the Mayo
Table 1 Characteristics of the Study Population
Number of patients 48
Number of men/women 38/10
Mean age at surgery (range; SD) 64.9 (38–79; 9.8)
Involvement of the right kidney (number) 37

















Number of clear cell carcinoma (%) 40 (83.3)
Number of papillary carcinoma (%) 7 (14.6)
Presence of preoperative metastases (number, %) 16 (33.3)
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staging system [16]: Level I refers to thrombi that extend
into the IVC to no more than 2 cm above the renal vein.
Level II represents IVC thrombi extending into into the
IVC to more than 2 cm above the renal vein but not to
the hepatic vein, whereby Levels I and II make up for
approximately 50% of the thrombi. Level III IVC
thrombi are defined as extending above the hepatic
veins, but below the diaphragm, making up for about
40%. Level IV IVC thrombi extend above the diaphragm
or into the right atrium and represent approximately
10% [17]. IVC thrombus levels for all patients were
assessed at two time points, first, during preoperative
imaging, and second by exploration during surgery.
With regard to the composition of IVC thrombus, an
image-based differentiation was performed for bland
thrombus, which was diagnosed, when there was no
thrombus enhancement, tumor thrombus, which was as-
sumed when the signal intensity was similar to that of the
RCC and mixed content, which included both features and
could e.g. also refer to a tumor thrombus covered by clot.
The maximum IVC diameters were measured on an
axial section in two directions, which were perpendicular
to each other.
Image analysis
All of the images were analyzed by use of PACS workstations
(Centricity Radiology; GE Healthcare). All MRI images were
evaluated by two radiologists blinded to the surgical and
pathological findings and to the observations of the other in
randomized order and in two different reading sessions,
which were separated by a period of 2 weeks. IVC thrombi
were analyzed based on the following properties: upper ex-
tent (infrahepatic, intrahepatic, infra-diaphragmatic or supra-
diaphragmatic), thrombus enhancement, IVC diameter and
wall invasion. If the IVC thrombus could clearly be delin-
eated from the vessel wall and if there was no thickening or
altered signal of the low-intensity vessel wall, invasion was
assumed to be absent. If there was a contact of the IVC
thrombus with or even a visual breach of the IVC wall, IVC
wall invasion was assumed to be present. More specifically,
contact to the vessel wall referred to a loss of delineation be-
tween thrombus and vessel wall with complete occlusion of
the vessel and blood signal loss in the affected area. Conse-
quently, a diagnosis of wall invasion was made, when the
tumor showed contact with the vessel wall or, if there was a
breach or extension through the vessel wall [9]. Agreement
between the two observers was also assessed. Finally, im-
aging findings were validated with intraoperative findings.
Intraoperative evaluation and procedure
Intraoperatively, wall invasion was reported, if the IVC
thrombus showed any adherence to the IVC wall. Ab-
sence of IVC wall invasion was confirmed, if the caval
thrombus could be easily removed.
If the IVC does not show any signs of advanced invasion
intraoperatively and there is no evidence of the resection
compromising the IVC lumen, the standard operative pro-
cedure at our institution involves a combination of thromb-
ectomy with subsequent cavorrhaphy, using continuous
polypropylene suturing. If there is advanced tumorous inva-
sion with a breach of the vessel wall IVC resection, either
segmental or circumferential, become necessary.
Statistical analysis
Statistical analysis was performed with “R” Statistical Soft-
ware (Version 3.2.2, R Development Core Team, 2015).
Variables were expressed as means ± standard deviations.
Sensitivity and specificity as well as the positive and nega-
tive predictive values were calculated based on the assess-
ments of the two readers for visual wall invasion. In case of
a differing assessment, the opposite of the reference stand-
ard (intraoperative finding) was assumed in order to avoid
an overestimation of the diagnostic performance. Cohen’s
kappa coefficient was used to measure interobserver
Table 2 Tabulated imaging parameters of the magnetic resonance sequences
Type of acquisition T2 HASTEa axial T2 HASTEa coronary T2 TSEb axial (PACE)b T1 FLASHc Angiography T1 FLASHc T1 VIBEd
Repetition time, TR (ms) 800 800 2430 186 2.88 4.74
Echo time, TE (ms) 94 89 79 4.76 0.98 2.38
Field of view (FOV) 340 × 340 400 × 400 340 × 340 340 × 340 500 × 500 373 × 373
Matrix size 320 × 320 320 × 320 320 × 320 320 × 320 512 × 512 320 × 320
Slice thickness (mm) 5 5 4 4 1.4 3
Pixel bandwidth (Hz/pixel) 300 422 260 260 440 400
Acquisition mode 2D 2D 2D 2D 3D 3D
Flip angle (°) 180 170 180 70 25 10
Voxel size 1.3 × 1.1 × 4.0 1.7 × 1.3 × 5.0 1.5 × 1.1 × 4.0 1.4 × 1.1 × 4.0 1.6 × 1.0 × 1.4 1.7 × 1.2 × 3.0
aHalf Fourier Single-shot Turbo-spin Echo sequence
bTurbo Spin Echo with Prospective Acquisition Correction
cFast low-angle shot magnetic resonance imaging
dVolumetric Interpolated Breath-hold Examination
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agreement for categorical variables (invasion/no invasion).
The intraclass coefficient (ICC) was used to assess interob-
server and intermodality reliability for continuous data. In-
terobserver and intermodality reliability was considered
poor for ICC/kappa values less than 0.40, fair for values
from 0.40–0.59, good for values from 0.60–0.74 and excel-
lent for values above 0.75. Furthermore, a logistic regres-
sion model was used to determine if there was an
association between intraoperative wall adherence and IVC
diameter. Fisher’s exact test was used to assess if thrombus
enhancement showed a significant association with IVC
wall invasion. A p-value < 0.05 was considered statistically
significant.
Results
All of the 48 patients underwent extended nephrectomy
and thrombectomy, with the information available from
surgery being used to confirm IVC wall invasion.
Validation with intraoperative findings
We found that contact of the IVC thrombus to or
breach of the vessel wall could reliably diagnose wall in-
vasion in preoperative MRI imaging with a sensitivity of
92.3% (95%-CI: 0.75–0.99) and a specificity of 86.4%
(95%-CI: 0.65–0.97) (Fisher test: p-value < 0.001). The
positive predictive value (PPV) was 88.9% (95%-CI: 0.
71–0.98) and the negative predictive value reached 90.
5% (95%-CI: 0.70–0.99) (refer to Table 3).
There were 26 cases of wall invasion, of which 24 were
correctly identified based on contrast-enhanced MRI (see
Figs. 1 and 2 for case examples). The two patients with IVC
invasion, who were considered to have a non-adherent
thrombus based on MRI, were revealed to have very small
areas of adherence (less than 1 cm) intraoperatively. In one
of these cases, the assessment of the observers differed. Of
the 22 cases, where intraoperative findings revealed no pres-
ence of wall invasion, 19 could be correctly identified with
MRI (see Fig. 3 for case example). In the three cases, where
MRI could not identify absence of wall invasion, this was
mostly due to respiratory motion artifacts on the axial im-
ages, with the observers’ evaluation differing in two of the
cases.
Interobserver agreement for IVC wall invasion
There was an excellent interobserver agreement for deter-
mining IVC wall invasion with a kappa coefficient of 0.95
(95%CI: 0.85–0.98). In three cases, the two observers
assessed the presence or absence of invasion differently,
whereby the opposite of the reference standard (findings
at surgery) was chosen in order to avoid an overestimation
of the diagnostic performance (see Table 4).
Regarding IVC diameter measurements, there was also
an excellent interobserver agreement with an ICC coeffi-
cient of 0.90 (95%CI: 0.79–1.00).
Association between IVC diameter and probability of IVC
invasion
Furthermore, we found that increases in IVC diameter were
associated with a higher probability of IVC wall invasion,
with the β-coefficient for the IVC diameter being 0.41
(standard error +/− 0.13). This influence also reached signifi-
cance level (p= 0.015). Patients with IVC wall invasion
showed a mean diameter of 42.96 mm±8.54 mm, while pa-
tients without wall invasion had a mean diameter 34.00 mm
±7.25 mm. This difference was also significant (p= 0.0.001).
By contrast, intraoperative IVC wall invasion was not
significantly related to the extent or level of IVC extent
(p > 0.05).
Assessment of IVC wall invasion based on MR
enhancement
A clear differentiation between invasive and noninvasive
IVC thrombus based on MR enhancement patterns proved
to be unfeasible, as enhancement was observed in 14 out of
the 22 cases without IVC invasion, indicating a high num-
ber of false positives. However, none of the non-enhancing
IVC thrombi showed signs of invasion, inferring a good es-
timate of the false negatives. Therefore, the association be-
tween enhancement and IVC invasion was significant
(Fisher test: p = 0.001). This matches the finding of a signifi-
cant association between the composition of the IVC
thrombus (if it was a bland thrombus/venous clot, a tumor
thrombus or an association of both) and enhancement.
While no enhancement could be observed in patients with
bland tumor thrombus, there was enhancement in patients
with tumor thrombus and mixed content.
Discussion
This study suggests that preoperative MR imaging enables
a reliable determination of IVC wall invasion in patients
with RCC. More specifically, complete occlusion of the IVC
lumen and breach of the vessel wall are indicators of IVC
invasion with a high sensitivity and specificity. Furthermore,
increases in IVC diameter were associated with a higher
probability of IVC wall invasion.
IVC wall invasion has recently been recognized as an in-
dependent prognostic factor for the survival of patients
Table 3 Diagnostic performance of MRI with surgery as the
reference standard
Observer 1 Observer 2 Observer 1
and 2 combined
Sensitivity 0.92 (0.75–0.99) 0.96 (0.80–1.0) 0.92 (0.75–0.99)
Specificity 0.95 (0.77–1.0) 0.86 (0.65–0.97) 0.86 (0.65–0.97)
Negative
predictive value
0.91 (0.72–0.99) 0.95 (0.75–1.0) 0.91 (0.70–0.99)
Positive
predictive value
0.96 (0.80–1.0) 0.89 (0.72–0.98) 0.89 (0.71–0.98)
Point estimates and 95% confidence intervals are indicated in brackets
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Fig. 1 Images in a 55-year old man with a clear cell renal cell carcinoma (RCC) and an inferior vena cava (IVC) tumor thrombus with wall
invasion. The RCC extends from the right kidney into the suprahepatic IVC. a axial fat-saturated T2-weighted image. b T1-weighted contrast-
enhanced 3D GRE (VIBE) image (arterial phase) and (c), coronal T2-weighted HASTE image for anatomic reference. Note that the thrombus
completely obstructs the lumen of the IVC and shows direct contact with the vessel wall (a, c). The contrast-enhanced image (b) demonstrates a
heterogeneous enhancement of the tumor thrombus, and contact to, but no breach of the vessel wall, which makes IVC wall invasion likely.
During extended nephrectomy, this thrombus was partly adherent the IVC and after extraction of the IVC thrombus, continuous suturing became
necessary. VIBE = Volumetric interpolated breath-hold examination
Fig. 2 Images in a 69-year old woman with a clear cell renal cell carcinoma (RCC) and an inferior vena cava (IVC) tumor thrombus with wall invasion.
The RCC extends from the right kidney into the IVC and extends into the right atrium. a axial fat-saturated T2-weighted image. b T1-weighted
contrast-enhanced 3D GRE (VIBE) image contrast enhanced 3D GRE image (arterial phase) and (c), coronal T2-weighted HASTE image for anatomic
reference. Note that the thrombus completely obstructs the lumen of the IVC, but also seems to breach the vessel wall (a, c). The contrast-enhanced
image (b) demonstrates a heterogeneous enhancement of the tumor thrombus and a clear breach of the vessel wall (gray arrowhead), which is highly
suggestive of IVC wall invasion. During extended nephrectomy, this thrombus showed strong adherence to the IVC wall and during extraction,
circumferential cavectomy with vascular reconstruction became necessary. VIBE = Volumetric interpolated breath-hold examination
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with IVC thrombi [16, 18–20]. During surgery, IVC wall
invasion requires a very challenging reconstruction be-
yond standard cavorrhaphy, that might include segmental
resection or prosthetic replacement. However, there has
been limited data with only a handful of studies and -
apart from the study by Psutka et al. - with small sample
sizes [9, 12, 14, 21, 22]. With regard to MR imaging, the
number of studies is even more limited, as Psutka et al.,
for example, chose a cross-sectional approach including
both MRI and CT images, with CT having a comparably
lower diagnostic performance, and using a combination of
multiple radiographic parameters to predict IVC invasion
[14]. By contrast, we propose a purely MR-based approach
with focus on the direct detection of IVC wall invasion
with clearly defined morphologic parameters.
In line with our results, previous studies found tumor
signal on both sides of the vessel wall to be one of the
most reliable indicators of vessel breach and of IVC wall
invasion [9, 12, 21]. Furthermore, Myneni et al. proposed
to use the low signal intensity line of the normal vessel
wall on gradient echo (GRE) and T1-weighted images as
a minor criterion for vessel wall invasion [13].
In addition, contrast enhancement of the thrombus or
venous wall has been suggested as a criterion for distin-
guishing tumor thrombus from bland thrombus and for
narrowing the diagnosis to wall invasion, the theory be-
ing that the neo-vascular bed of the tumor thrombus
would adhere to the venous wall, whereas the bland
thrombus would not [9, 12]. In the present study,
thrombus enhancement was not reliable for excluding
caval wall invasion, as enhancement was observed in
more than 60% of the cases, where no wall invasion was
found intraoperatively. However, it proved to be reliable
Fig. 3 Images in a 79-year old woman with a clear cell renal cell carcinoma (RCC) and bland inferior vena cava (IVC) thrombus without wall
invasion. The RCC extends from the right kidney into the infrahepatic IVC. a axial T2-weighted HASTE image. b T1-weighted contrast-enhanced
3D GRE (VIBE) image and (c), the coronal T2-weighted HASTE image for anatomic reference. Note that the thrombus is floating in the IVC and
that there is no complete obstruction of the caval lumen (a, c). The contrast-enhanced image (b) demonstrates that there is no enhancement of
the tumor thrombus, contact to or breach of the vessel wall, so that IVC wall invasion appears unlikely. During extended nephrectomy, this
thrombus could be easily removed from the IVC without necessitating segmental resection. HASTE = Half-Fourier-acquired singe-shot turbo spin
echo, VIBE = Volumetric interpolated breath-hold examination
Table 4 Wall invasion by inferior vena cava thrombus on MRI
versus invasion determined at surgery
Observer 1 MRI Surgery
Wall invasion Absence of wall invasion
Wall invasion 24 1
Absence of wall invasion 2 21
Observer 2 MRI Surgery
Wall invasion Absence of wall invasion
Wall invasion 25 3
Absence of wall invasion 1 19
Observers 1 + 2 MRI Surgery
Wall invasion Absence of wall invasion
Wall invasion 24 3
Absence of wall invasion 2 19
In three cases, the two observers assessed the presence or absence of
invasion differently. In case of a differing assessment, the opposite of the
reference standard (intraoperative finding) was assumed in order to avoid an
overestimation of the diagnostic performance. This combined assessment
(observers 1 + 2) is shown below
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for excluding invasion in cases, where no IVC enhance-
ment was observed.
Furthermore, previous studies demonstrated an associ-
ation between IVC diameters and wall invasion [14, 23].
Psutka et al. considered 24 mm or more on the level of
the renal vein ostium to be a probable indicator of ad-
vanced IVC invasion [14, 23]. In the present study, prob-
ability of IVC wall invasion also was higher with
increasing IVC diameters, which appears logical, as big-
ger thrombi show a higher propensity for invasion.
The presence of IVC wall invasion has also been incor-
porated into the American Joint Committee on Cancer
(AJCC) cancer staging criteria for RCC, changing a stage
T3b to a stage T3c [24].
Previous research suggested a superior diagnostic ac-
curacy of MRI in detecting the upper extent of IVC
thrombus due to its intrinsic contrast superiority [25].
However, in more recent studies, the diagnostic per-
formance of CT and MRI in staging the level of IVC
thrombus has been regarded to be similar [26–29]. How-
ever, to our knowledge there has not been a systematic
comparison between multidetector CT and MRI con-
cerning the detection of IVC wall invasion yet.
Even though it has to be acknowledged, that the pre-
operative assessment of IVC invasion cannot replace the
value of surgical exploration, morphologic MR features
may be used to predict the risk for complicated inferior
vena cava resection in a reproducible manner, which is
also supported by the strong interobserver agreement we
found. In clinical practice, surgeons can use the additional
information to optimize their preoperative planning, e.g.
in consultation with the vascular surgeons or scheduling
of the most experienced surgeons. The derived informa-
tion is especially important in patients, in whom recon-
struction of the IVC beyond cavorrhaphy is probable, to
determine the need for specific operative resources (e.g.
cardiopulmonary bypass) in advance and also to individu-
ally improve prior patient information [15]. Intraopera-
tively, the a priori assessment of wall invasion can be a
helpful adjunct to additional examinations such as duplex
ultrasound or transesophageal echocardiography, which
can be used to further characterize the mobility,
consistency and the exact extension of the thrombus [14].
Recent studies have focused on diffusion weighted imaging
(DWI) as an emerging technique for quantitative readouts,
with the apparent diffusions coefficient (ADC) values repre-
senting tumor cellularity [30]. DWI has shown promise in
preoperative cancer staging, e.g. for endometrial, cervical,
bladder, rectal or gastric cancer [31–34]. Especially the
introduction of reduced field-of-view (FOV) techniques has
enabled an improved tumor delineation with higher spatial
resolution, decreased partial volume averaging and less sus-
ceptibility distortion [35]. Future studies on the preoperative
evaluation of IVC invasion could, therefore, include reduced
FOV DWI sequences to investigate whether additional
information on thrombus composition may be gained. Fur-
thermore, functional imaging, such as dynamic contrast en-
hanced (DCE) MRI, may improve assessment of thrombus
and wall enhancement through the quantification of contrast-
enhancement characteristics and the evaluation of microcir-
culation parameters. During DCE imaging, several contrast
enhancement parameters can be used to better differentiate
tumor tissue. Previous research suggested, that especially the
early postcontrast phase could be relevant for tumor detec-
tion [36]. By contrast, there were also studies suggesting, that
there was limited additional value for diagnosis of clinically
relevant cancer [37]. Two notable disadvantages of the semi-
quantitative parameters derived from DCE imaging is their
direct estimation from the signal intensity measurements
without physiological or empirical correlation and also their
dependence on experimental factors such as sequence param-
eters or contrast dose, especially limiting their comparability
and reproducibility between different sites [38].
In the present study, patients did not receive dynamic
imaging, but only an early postcontrast phase. In everyday
clinical practice, the time required for extensive examin-
ation protocols can be limited. Therefore, the objective of
the present study was to test the performance and feasibil-
ity of a relatively short standard protocol for the preopera-
tive evaluation of inferior vena cava wall invasion.
Regarding the results of the present study for MRI, the
high sensitivity (92.3%) indicates, that the presence of IVC
invasion is rarely underestimated and the high negative pre-
dictive value (90.5%) suggests, that if the IVC thrombus
does not show any contact with the vessel wall, an IVC wall
invasion can be reliably excluded. The comparably lower
specificity shows, that a visual contact of the IVC thrombus
with the vessel wall does not always correspond to IVC wall
invasion, but still in more than 85% of the cases.
The excellent interobserver agreement for the assess-
ment indicates the feasibility of using MR features for
assessing IVC thrombus invasion in clinical practice.
Complete occlusion of the IVC lumen or breach of the
vessel wall may be used to predict the presence of IVC
wall invasion and thus of complicated surgery.
This study has some limitations. Firstly, different MRI
scanners were included over a relatively long period of time,
resulting in a potential variability across scanners and im-
aging sessions, where the same scanner is used. Secondly,
due to its retrospective design, a potential selection bias
cannot be excluded. Thirdly, as intraoperative findings were
used as the reference standard for wall invasion, presence
of microscopic invasion cannot be excluded. Fourthly, as
the present study is single center, external validation of the
applied MR features is warranted. Furthermore, the
addition of DWI or DCE imaging to the protocol might
have further improved the preoperative assessment of IVC
thrombus. Finally, MR imaging is contraindicated in some
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patients, e.g. patients with pacemakers, metallic foreign
bodies or with severe claustrophobia.
Conclusions
This study indicates that standard preoperative MR im-
aging can be used to reliably assess IVC wall invasion,
evaluating morphologic features such as the complete
occlusion of the IVC lumen or vessel breach. The excel-
lent interobserver agreement suggests an adequate re-
producibility of the preoperative assessment in clinical
practice. In future, MR morphologic features might be
used to refine preoperative planning and improve prior
patient information.
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